These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents. Knapp E; Cohen H; Kutlar A; Ghalie R; Manwani D Am J Hematol; 2016 Mar; 91(3):E11-2. PubMed ID: 26661045 [No Abstract] [Full Text] [Related]
11. Genetic Therapies for Sickle Cell Disease. Jayavaradhan R; Malik P Pediatr Clin North Am; 2018 Jun; 65(3):465-480. PubMed ID: 29803277 [TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea for sickle cell anemia. Naina HV; Harris S N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283 [No Abstract] [Full Text] [Related]
13. Treatment Options for Sickle Cell Disease. Meier ER Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275 [TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea, sickle cell disease and renal transplantation. Allen A; Scoble J; Snowden S; Hambley H; Bellingham A Nephron; 1997; 75(1):106-7. PubMed ID: 9031282 [No Abstract] [Full Text] [Related]
15. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease? Segel GB; Simon W; Lichtman MA Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473 [No Abstract] [Full Text] [Related]